Ann: Imugene B Cell & OV Platforms Featured at ESMO Congress, page-100

HER-Vaxx-based vaccination of patients with HER-2-overexpressing GC, induced anti-HER-2-IgG and IgG1 subclass antibody responses (p<0.001) with dose-dependent functionality in
binding to Her-2/neu-expressing cells and intracellular phosphorylation inhibition of the receptor and the signaling pathway kinases Akt and MAPK

Ms Leslie Chong needs to expand further, the significance behind the science of both :-
Binding to Her-2/neu-expressing cells.
Intracellular phosphorylation inhibition of the receptor and the signaling pathway kinases Akt and MAPK.

Big pharma would already know,
The Akt pathway in oncology therapy and beyond (Review)
https://pubmed.ncbi.nlm.nih.gov/30334567/

MAPK phosphatases — regulating the immune response
https://www.nature.com/articles/nri2035

Regards.